Paul Hastings Advises on Goldman Sachs Alternatives' Synthon Acquisition

Paul Hastings LLP has played a pivotal advisory role in the financing aspect of the Goldman Sachs Alternatives' acquisition of Synthon, a company specializing in complex generic medications. This transaction involves the acquisition of a majority stake from BC Partners, although BC Partners will maintain a significant share in Synthon. The transaction was overseen by a team from Paul Hastings led by partners Ross Anderson and Patrick Bright, with additional expertise provided by other partners and associates from the firm. Synthon is recognized for its innovation in the development, manufacturing, and out-licensing of generic drugs, suggesting that Goldman Sachs Alternatives sees significant strategic value in this acquisition. Paul Hastings, known for its expertise in finance and M&A, provided crucial support and guidance during this transaction, underscoring its role as a key player in high-profile global legal advisory services.